BiotechTube
MygoGenesis

MygoGenesis

San Diego, United States· Est.
mygogenesis.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Founded in 2018 and based in San Diego, MygoGenesis is a private, pre-revenue biotech developing a novel cellular reprogramming platform. Its core technology, the Mygotic Process™, claims to create totipotent cells from a patient's own somatic cells, potentially bypassing challenges associated with iPSCs or embryonic stem cells. The company is pursuing a diversified strategy, aiming to spin out subsidiary companies focused on specific applications like universal blood production, cell banking, and sustainable reagents for endotoxin testing.

Regenerative MedicineOncologyCardiovascularNeurologyDiabetes

Technology Platform

Mygotic Process™: A proprietary cellular reprogramming technology that converts somatic cells into autologous totipotent cells by erasing epigenetics without altering DNA, enabling differentiation into any cell or tissue type.

Opportunities

The company's platform, if validated, addresses massive markets in regenerative medicine, organ transplantation, and blood supply, offering potentially curative autologous therapies.
Its non-therapeutic application in sustainable LAL production provides a nearer-term path to revenue in a established testing market.

Risk Factors

The core scientific claims of creating safe, functional totipotent cells are unproven and face significant validation, manufacturing, and regulatory hurdles.
The ambitious, multi-program strategy requires enormous capital and risks diluting focus in a highly competitive field.

Competitive Landscape

MygoGenesis faces intense competition from established iPSC companies (e.g., Fate Therapeutics, Century Therapeutics), gene editing firms, and organoid/bioprinting ventures. In LAL testing, it would compete with traditional horseshoe crab harvesters and existing recombinant factor C (rFC) alternatives.

More companies in Cell & Gene Therapy →More companies in United States →